TiumBio Co., Ltd. 321550

KRX · South Korea · Health Technology

KRW 4,525.00-370.00 (-7.56%)

Market closed· Oct 2, 2026, 6:30 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

TiumBio Co., Ltd. 321550

KRX · South Korea · Health Technology

KRW 4,525.00-370.00 (-7.56%)

Market closed· Oct 2, 2026, 6:30 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-58.90% · 6MFull-screen chart

Open KRW 4,935.00High KRW 4,940.00Low KRW 4,485.00Close KRW 4,525.00Volume 231.68K

Oct 2, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: KRW 4,895.00
Day range: KRW 4,485.00 – KRW 4,940.00
52-week range: KRW 3,415.00 – KRW 13,700.00
Volume: 231.68K
Market cap: KRW 147.04B
Avg. volume (1Y): 335.04K

Performance

1 week

+0.56%

1 month

+4.26%

3 months

+13.41%

6 months

-55.51%

Year to date

-26.30%

1 year

-17.73%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Country: South Korea
Exchange: KRX
Shares outstanding: 30.04M
Employees: 67
ISIN: KR7321550006
Beta: -0.29

Technical view

Mixed

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceMay 31, 2026

TiumBio to Present Phase 2a Interim Data Highlighting Differentiated Clinical Profile for Tosposertib(TU2218) plus Pembrolizumab in First-Line R/M HNSCC at ASCO 2026

TiumBio Co., Ltd. (KOSDAQ: 321550), a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics, announced clinical data for Tosposertib (TU2218), an oral dual inhibitor targeting transforming growth factor-beta (TGF-β) and vascular endothelial growth factor (VEGF), in first-line (1L) recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) at American Society of Clinical Oncology (ASCO) 2026.

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.